• Map the data-gathering needs of multiyear therapeutics with undefined benefits, in a system that is typically PAYGO • Establish a timeline for value-based checks and rebates • Find the best approach towards CMS Best Price Reporting and determine if rebates can become more substantial • Maintain dialogue with CMS and payers
